Technology

Relmada Therapeutics

$35.56
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.17 (-0.48%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell RLMD and other stocks, options, and ETFs commission-free!

About RLMD

Relmada Therapeutics, Inc. Common Stock, also called Relmada Therapeutics, is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY. The listed name for RLMD is Relmada Therapeutics, Inc. Common Stock.

CEO
Sergio Traversa
Employees
4
Headquarters
New York, New York
Founded
2012
Market Cap
591.13M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
76.30K
High Today
$36.02
Low Today
$34.90
Open Price
$36.02
Volume
41.23K
52 Week High
$54.00
52 Week Low
$23.25

Collections

RLMD Earnings

-$1.05
-$0.70
-$0.35
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 10, After Hours

You May Also Like

ITT
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure